Roth E F, Schiliro G, Russo A, Musumeci S, Rachmilewitz E, Neske V, Nagel R
J Med Genet. 1980 Feb;17(1):34-8. doi: 10.1136/jmg.17.1.34.
The chemical and physical properties of haemoglobin S derived from homozygotes for this haemoglobin in Sicily were examined, as well as some erythrocytic characteristics. Sicilian Hb S was identical to that found in USA black patients in electrophoretic mobility on both starch and citrate agar media, solubility, mechanical precipitation rate of oxyhaemoglobins, and minimum gelling concentration, as well as by peptide mapping and amino-acid analysis of all beta-chain peptides. Taken together with the presence in Sicily of African blood group markers and certain historical considerations, it seems clear that the source of Hb S in Sicily is Africa. While the clinical severity in nine Sicilian children did not seem remarkably different from the disease in the USA, the most severe and fatal complications were not seen. Mean Hb F Was 10.5% and 2,3-diphosphoglycerate (2,3-DPG) values were higher in Sicilian homozygotes than in black USA counterparts (21.79 mumol/g Hb vs 15.16). Red cell AT values were also slightly higher in Sicilian patients. The presence of concomitant thalassaemia was excluded by both family studies and globin chain synthetic ratios. In conclusion, haemoglobin S in Sicilian homozygotes is identical to Hb S found in USA blacks. Although the severity of the disease seems quite similar in both groups of patients, other erythrocytic properties were found to be different. Whether these factors influence severity remains to be elucidated.
对来自西西里岛该血红蛋白纯合子的血红蛋白S的化学和物理性质以及一些红细胞特征进行了研究。西西里岛的血红蛋白S在淀粉和柠檬酸盐琼脂培养基上的电泳迁移率、溶解度、氧合血红蛋白的机械沉淀率、最低胶凝浓度,以及通过所有β链肽的肽图谱分析和氨基酸分析,均与在美国黑人患者中发现的血红蛋白S相同。结合西西里岛存在非洲血型标记以及某些历史因素来看,西西里岛血红蛋白S的来源显然是非洲。虽然9名西西里岛儿童的临床严重程度似乎与美国患者的病情没有显著差异,但未观察到最严重和致命的并发症。西西里岛纯合子的平均血红蛋白F为10.5%,2,3 - 二磷酸甘油酸(2,3 - DPG)值高于美国黑人患者(21.79μmol/g血红蛋白对15.16)。西西里岛患者的红细胞AT值也略高。通过家族研究和珠蛋白链合成比率排除了合并地中海贫血的存在。总之,西西里岛纯合子中的血红蛋白S与美国黑人中发现的血红蛋白S相同。虽然两组患者疾病的严重程度似乎相当相似,但发现其他红细胞特性有所不同。这些因素是否影响严重程度仍有待阐明。